Recent content by jondoeuk

Amplifica raised $26 million in a Series B Preferred Stock financing round. Of particular note, one of the investors is Eli Lilly (US), which also invested in Absci (US) earlier this year...

Amplifica published five-month results of a 61-person trial of AMP-303, described as a novel polysaccharide. https://www.jidonline.org/article/S0022-202X(25)01992-X/fulltext The male subjects (all aged 18-45) with mild to moderate androgenetic alopecia (Norwood III-IV) were divided into two...

Amplifica's AMP-303 phase one trial results came out: ''A statistically significant percentage of study subjects showed a greater than 15% increase in non-vellus hair count from baseline compared to placebo at 60 days post-treatment, and a greater than 10% increase compared to placebo at 150...

More here https://www.wired.com/story/a-hair-loss-study-raises-new-questions-about-aging-cells/

Kintor plans to initiate a phase IIb/III clinical trial of pyrilutamide in combination with minoxidil for the treatment of male androgenetic alopecia in China this year.

GT20029 1% BIW (twice per week application).

''In an independent ex vivo human Androgenetic Alopecia model — conducted using intact human hair follicles from male patients with Androgenetic Alopecia, challenged with dihydrotestosterone (DHT) to replicate the follicular miniaturization environment seen in Androgenetic Alopecia patients — RLS‑1496 demonstrated statistically and highly...

Rubedo Life Sciences announced that it would start a clinical trial in 2026 to test its GPX4 modulator to treat hair loss...

Yes.

''The study met its primary safety endpoint and secondary pharmacokinetic endpoint: the drug was well tolerated with no systemic absorption of PP405 detected in the blood, underscoring a robust safety profile.''...

Overall skin aging is also driven by sun exposure, genetics, a natural drop in structural proteins over time, lifestyle factors, and more.

Dihydrotestosterone can contribute to skin aging by inhibiting elastin production. https://www.youtube.com/playlist?list=PLXoKcD0kKb9bMHV9YJcXcJcuPI5PjO1pj https://www.youtube.com/playlist?list=PLXoKcD0kKb9Z3tiWUPJStX-ys-lei8xXp

Unlike oral finasteride or dutasteride, which reduce systemic DHT levels, pyrilutamide is designed to work locally with a different mechanism of action, so is a good option for those that can't or won't take finasteride or dutasteride. Pyrilutamide 1.0% BID (twice daily): +15.33 hairs/cm² from...

It is critical to distinguish between a drug losing all efficacy and a drug peaking and stabilising. According to top-line data from Kintor's year-long study, patients using 0.5% pyrilutamide twice daily still experienced significant increases in target area hair count (TAHC) and hair width...

Yes. (2026-03-18) ''In terms of efficacy: compared to the placebo group, both 1.0% BID (i.e. twice a day) group and 0.5% BID group demonstrated statistically significant therapeutic efficacy and clinical significance. The target area non-vellus hair counts (“TAHC”) of the 1.0% BID group showed...